Vebreltinib Explained

Drug Name:	Vebreltinib
Routes Of Administration:	Oral
Legal Status:	Rx in China
Synonyms:	Bozitinib; APL-101; PBL-1001
Cas Number:	1440964-89-5
Pubchem:	72202701
Chemspiderid:	72388443
Unii:	2WZP8A9VFN
Drugbank:	DB16823
Chembl:	4650443
Iupac Name:	6-(1-Cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-''b'']pyridazine
C:	20
H:	15
F:	3
N:	8
Smiles:	CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
Stdinchi:	1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
Stdinchikey:	QHXLXUIZUCJRKV-UHFFFAOYSA-N

Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer.^{[1] [2]}

Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.^[3]

In China, it is approved for the treatment of non-small-cell lung cancer (NSCLC) with MET exon 14 skipping mutations.^[4]

Notes and References

1. Hong L, Zhang J, Heymach JV, Le X . Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer . Therapeutic Advances in Medical Oncology . 13 . 1758835921992976 . 2021 . 33643443 . 10.1177/1758835921992976 . 7890719 .
2. Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, Jin R, Le X, Li W, Xia Y . Targeting MET in NSCLC: An Ever-Expanding Territory . JTO Clinical and Research Reports . 5 . 2 . 100630 . February 2024 . 38361739 . 10867448 . 10.1016/j.jtocrr.2023.100630 .
3. Web site: Vebreltinib . NCI Drug Dictionary . U.S. National Institutes of Health .
4. News: Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC . onclive.com . November 16, 2023 .